AN2 Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AN2 Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $39.00K, a 2.63% increase year-over-year.
- AN2 Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $48.00K, a 108.70% increase year-over-year.
- AN2 Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $38.00K, a 69.35% decline year-over-year.
- AN2 Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $23.00K, a 86.23% decline year-over-year.
- AN2 Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $86.00K, a 41.50% decline from fiscal 2024.
- AN2 Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $147.00K, a 59.84% decline from fiscal 2023.
- AN2 Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $366.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-03-31 | $39.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $86.00K 10-K · filed 2026-03-17 | |
| 2025-09-30 | $48.00K 10-Q · filed 2025-11-12 | |
| 2025-03-31 | $38.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $147.00K 10-K · filed 2026-03-17 | |
| 2024-09-30 | $23.00K 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $124.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $366.00K 10-K · filed 2025-03-25 | |
| 2023-09-30 | $167.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $199.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |